Ziihera®（Zanidatamab-Hrii）联合治疗方案在针对HER2阳性局部晚期或转移性胃食管腺癌的一线治疗中展现出前所未有的疗效，其中位总生存期获益已突破两年大关。
这一里程碑式数据不仅刷新了该类疾病领域的治疗纪录，更凸显了双特异性抗体药物在攻克难治性肿瘤方面的巨大潜力。临床观察显示，接受联合治疗的患者群体在肿瘤缩小率、无进展生存期等关键指标上均获得显著改善。
随着个体化医疗时代的到来，靶向药物组合策略正逐步重塑晚期胃癌的治疗格局。研究者指出，持续超两年的生存获益为患者提供了长期高质量生活的可能，同时也为后续免疫联合疗法的开发奠定了坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.